Cover Image
QR Code

Hormone replacement therapy: optimising the dose and route of administration.

Several new products and regimens for estrogen replacement in the postmenopausal woman have recently been introduced, giving physicians and patients greater choice not only in dose but also in route of administration. Estrogen treatment in the postmenopausal woman has several proven benefits for tho...

Full description

Published in:Drugs & Aging Vol. 19; no. 11; pp. 807 - 819
Main Author: Rice VM
Format: review tables/charts Journal Article
Published: Springer Nature 2002
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106868466&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106868466
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        1170229X
        C5B
      jtl: Drugs & Aging
      issn: 1170229X
      maglogo: N
    pubinfo:
      dt: 2002
      vid: 19
      iid: 11
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        106868466
        2003125192
        10.2165/00002512-200219110-00001
        NLM12428992
        106868466
      ppf: 807
      ppct: 12
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Hormone replacement therapy: optimising the dose and route of administration.
      aug:
        au: Rice VM
        affil: Dept of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, KS
      sug:
        subj:
          Hormone Replacement Therapy Methods
          Administration, Oral
          Administration, Transcutaneous
          Amenorrhea
          Cardiovascular System Drug Effects
          Clinical Trials
          Drug Therapy, Combination
          Estrogens Therapeutic Use
          Hemorrhage Etiology
          Osteoporosis Drug Therapy
          Osteoporosis Prevention and Control
          Postmenopause Drug Effects
          Time Factors
      ab: Several new products and regimens for estrogen replacement in the postmenopausal woman have recently been introduced, giving physicians and patients greater choice not only in dose but also in route of administration. Estrogen treatment in the postmenopausal woman has several proven benefits for those who have vasomotor symptoms or problems related to urogenital atrophy. However, the most controversial area is in the long-term preventive benefits of estrogen against the development of osteoporosis and cardiovascular disease, particularly in women older than 60 years. It is in these areas that decisions on the dose and optimal route of administration of estrogen replacement therapy (ERT) must be made. Although adding a progestogen to an ERT regimen is mandatory, particularly in a woman with an intact uterus, discussion now focuses on which progestogen least attenuates the beneficial effects of estrogen. Emerging trends suggest that lower doses of estrogen (i.e. ethinylestradiol 5 microg/day, estradiol 0.25 mg/day or conjugated estrogens [CEE] 0.3 mg/day) continuously combined with lower doses of medroxyprogesterone (MPA) are equally effective at relieving vasomotor symptoms as the most commonly prescribed regimen in the US (CEE 0.625mg/MPA 2.5mg daily), with fewer adverse events, leading to greater patient acceptance and likelihood for continuation of therapy. This is especially important when therapy is initiated at an older age.
      pubtype: Academic Journal
      doctype:
        review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N